Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Biodexa Pharmaceuticals Reports 12-Month Phase 2 Trial Results For eRapa In Treating Familial Adenomatous Polyposis

Author: Benzinga Newsdesk | July 11, 2024 08:33am

17% Median Decrease In Polyp Burden, 75% Non-Progression Rate; Cohort 2 Shows 89% Non-Progressors And 29% Median Polyp Reduction; Potential First Therapeutic Option For FAP

Posted In: BDRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist